Cellectar Biosciences Inc
CLRB4.946USD
+0.226+4.79%
Market hours （ET）Quotes delayed by 15 min
7.60MMarket Cap
LossP/E TTM
More Details of Cellectar Biosciences Inc Company
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Company Info
Ticker SymbolCLRB
Company nameCellectar Biosciences Inc
IPO dateMay 20, 2005
CEOMr. James V. Caruso
Number of employees11
Security typeOrdinary Share
Fiscal year-endMay 20
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code07932
Phone16084418120
Websitehttps://www.cellectar.com/
Ticker SymbolCLRB
IPO dateMay 20, 2005
CEOMr. James V. Caruso
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Mr. John P. Neis
Mr. John P. Neis
Independent Director
Independent Director
--
--
Dr. Asher Alban Chanan-Khan, M.D.
Dr. Asher Alban Chanan-Khan, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jarrod Longcor
Mr. Jarrod Longcor
Chief Operating Officer
Chief Operating Officer
12.77K
+360.88%
Mr. James V. Caruso
Mr. James V. Caruso
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.64K
+609.38%
Mr. Chad J. Kolean
Mr. Chad J. Kolean
Chief Financial Officer, Vice President, Secretary
Chief Financial Officer, Vice President, Secretary
6.42K
+352.36%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Independent Chairman of the Board
Independent Chairman of the Board
83.00
--
Mr. Stefan D. Loren, Ph.D.
Mr. Stefan D. Loren, Ph.D.
Independent Director
Independent Director
--
--
Mr. Frederick W. (Fred) Driscoll
Mr. Frederick W. (Fred) Driscoll
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 26
Updated: Sat, Jul 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
2.14%
UBS Financial Services, Inc.
1.11%
Adar1 Capital Management LLC
0.68%
Lytton (Laurence W)
0.63%
Geode Capital Management, L.L.C.
0.55%
Other
94.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
3.70%
Individual Investor
1.91%
Investment Advisor/Hedge Fund
1.28%
Hedge Fund
1.21%
Corporation
0.36%
Research Firm
0.23%
Venture Capital
0.13%
Bank and Trust
0.03%
Other
91.15%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
84
202.41K
7.72%
-340.14K
2025Q1
86
199.12K
11.22%
-346.61K
2024Q4
85
5.89M
13.20%
-10.24M
2024Q3
82
15.21M
37.53%
+860.01K
2024Q2
87
12.77M
37.42%
+1.31M
2024Q1
84
10.31M
32.95%
-1.69M
2023Q4
71
9.17M
43.97%
+2.46M
2023Q3
74
3.14M
32.62%
+389.97K
2023Q2
83
3.71M
38.83%
+394.07K
2023Q1
91
3.81M
40.21%
+165.83K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
57.40K
2.14%
-172.00
-0.30%
Mar 31, 2025
UBS Financial Services, Inc.
29.84K
1.11%
+17.42K
+140.12%
Mar 31, 2025
Adar1 Capital Management LLC
18.19K
0.68%
+16.85K
+1256.45%
Apr 17, 2025
Lytton (Laurence W)
16.78K
0.63%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
14.78K
0.55%
+3.08K
+26.38%
Mar 31, 2025
Longcor (Jarrod)
2.77K
0.18%
+1.00K
+56.47%
Apr 17, 2025
Squarepoint Capital LLP
12.36K
0.46%
-4.98K
-28.71%
Mar 31, 2025
Caruso (James V)
1.64K
0.11%
--
--
Apr 17, 2025
Citadel Advisors LLC
11.44K
0.43%
+11.44K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Date
Type
Ratio
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
Jul 21, 2022
Merger
10<1
